Norbert Bischofberger Is The President of Kronos Bio, Inc. (NASDAQ:KRON) And They Just Picked Up 11% More Shares
Kronos Bio, Inc. (NASDAQ:KRON) shareholders (or potential shareholders) will be happy to see that the President, Norbert Bischofberger, recently bought a whopping US$2.3m worth of stock, at a price of US$3.77. Aside from being a solid chunk in its own right, the deft move also saw their holding increase by some 11%.
See our latest analysis for Kronos Bio
The Last 12 Months Of Insider Transactions At Kronos Bio
Notably, that recent purchase by Norbert Bischofberger is the biggest insider purchase of Kronos Bio shares that we've seen in the last year. That means that even when the share price was higher than US$3.81 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.
Over the last year, we can see that insiders have bought 614.24k shares worth US$2.5m. But they sold 27.79k shares for US$344k. In the last twelve months there was more buying than selling by Kronos Bio insiders. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).
Does Kronos Bio Boast High Insider Ownership?
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. It appears that Kronos Bio insiders own 15% of the company, worth about US$33m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
So What Does This Data Suggest About Kronos Bio Insiders?
It's certainly positive to see the recent insider purchase. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Given that insiders also own a fair bit of Kronos Bio we think they are probably pretty confident of a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Kronos Bio. To that end, you should learn about the 4 warning signs we've spotted with Kronos Bio (including 2 which are a bit unpleasant).
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
